JPWO2020252129A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020252129A5 JPWO2020252129A5 JP2021573404A JP2021573404A JPWO2020252129A5 JP WO2020252129 A5 JPWO2020252129 A5 JP WO2020252129A5 JP 2021573404 A JP2021573404 A JP 2021573404A JP 2021573404 A JP2021573404 A JP 2021573404A JP WO2020252129 A5 JPWO2020252129 A5 JP WO2020252129A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- medicament according
- miglastat
- administered
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859904P | 2019-06-11 | 2019-06-11 | |
| US62/859,904 | 2019-06-11 | ||
| PCT/US2020/037174 WO2020252129A1 (en) | 2019-06-11 | 2020-06-11 | Methods of treating fabry disease in patients having renal impairment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022536687A JP2022536687A (ja) | 2022-08-18 |
| JPWO2020252129A5 true JPWO2020252129A5 (zh) | 2023-06-20 |
Family
ID=71950725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573404A Pending JP2022536687A (ja) | 2019-06-11 | 2020-06-11 | 腎機能障害を有する患者のファブリー病を治療する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220313670A1 (zh) |
| EP (1) | EP3982962A1 (zh) |
| JP (1) | JP2022536687A (zh) |
| KR (1) | KR20220019796A (zh) |
| CN (1) | CN114423427A (zh) |
| AR (1) | AR120055A1 (zh) |
| AU (1) | AU2020291002A1 (zh) |
| BR (1) | BR112021024886A2 (zh) |
| CA (1) | CA3141226A1 (zh) |
| CL (1) | CL2021003280A1 (zh) |
| EA (1) | EA202290024A1 (zh) |
| IL (1) | IL288677A (zh) |
| MX (1) | MX2021015352A (zh) |
| TW (1) | TW202112372A (zh) |
| WO (1) | WO2020252129A1 (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007253900A1 (en) | 2006-05-16 | 2007-11-29 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for fabry disease |
| AU2009214648B2 (en) | 2008-02-12 | 2014-11-13 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| AU2018277756A1 (en) | 2017-05-30 | 2020-01-23 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| JP7555818B2 (ja) | 2018-02-06 | 2024-09-25 | アミカス セラピューティックス インコーポレイテッド | 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用 |
| EP3895708A3 (en) | 2019-08-07 | 2022-01-19 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having a mutation in the gla gene |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US20100113517A1 (en) | 2007-03-30 | 2010-05-06 | Amicus Therapeutics, Inc. | Method for the treatment of fabry disease using pharmacological chaperones |
| EP2150254A4 (en) * | 2007-04-26 | 2010-11-10 | Amicus Therapeutics Inc | DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES |
| AU2009214648B2 (en) | 2008-02-12 | 2014-11-13 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| KR20140011367A (ko) * | 2011-03-11 | 2014-01-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 파브리 병을 치료하기 위한 투여 요법 |
| CA3031249A1 (en) * | 2016-07-19 | 2018-01-25 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naive and ert-experienced patients |
| MX2019008076A (es) * | 2017-01-05 | 2019-08-29 | Protalix Ltd | Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada. |
| AR111971A1 (es) * | 2017-05-30 | 2019-09-04 | Amicus Therapeutics Inc | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal |
| AU2018277756A1 (en) * | 2017-05-30 | 2020-01-23 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
-
2020
- 2020-06-11 EA EA202290024A patent/EA202290024A1/ru unknown
- 2020-06-11 BR BR112021024886A patent/BR112021024886A2/pt unknown
- 2020-06-11 CN CN202080042938.3A patent/CN114423427A/zh active Pending
- 2020-06-11 MX MX2021015352A patent/MX2021015352A/es unknown
- 2020-06-11 AR ARP200101648A patent/AR120055A1/es unknown
- 2020-06-11 WO PCT/US2020/037174 patent/WO2020252129A1/en unknown
- 2020-06-11 KR KR1020227000878A patent/KR20220019796A/ko unknown
- 2020-06-11 JP JP2021573404A patent/JP2022536687A/ja active Pending
- 2020-06-11 US US17/618,277 patent/US20220313670A1/en active Pending
- 2020-06-11 AU AU2020291002A patent/AU2020291002A1/en active Pending
- 2020-06-11 EP EP20751716.0A patent/EP3982962A1/en active Pending
- 2020-06-11 TW TW109119640A patent/TW202112372A/zh unknown
- 2020-06-11 CA CA3141226A patent/CA3141226A1/en active Pending
-
2021
- 2021-12-05 IL IL288677A patent/IL288677A/en unknown
- 2021-12-09 CL CL2021003280A patent/CL2021003280A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020196750A (ja) | 線維症を処置するためのセニクリビロック併用療法 | |
| EP1741446B1 (en) | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents | |
| KR101868991B1 (ko) | 피라졸 유도체 및 그 의약용도 | |
| US11033532B2 (en) | Uses of benzimidazole derivative for nocturnal acid breakthrough | |
| WO1999029327A1 (en) | Use of alpha-glucosidase inhibitors for treating high-risk impaired glucose tolerance | |
| EA015382B1 (ru) | Применение рофлумиласта для лечения сахарного диабета типа 2 | |
| BR112014023795B1 (pt) | Uso de inibidores de ccr3 | |
| JPH10510241A (ja) | Ｉｉ型糖尿病治療薬剤としてのケトコナゾール、および、その関連物質の使用法 | |
| JP2015537009A (ja) | 痛風の治療におけるブシラミンの使用 | |
| RU2070042C1 (ru) | Средство для лечения слабоумия, обусловленного цереброваскулярной патологией и болезнью альцгеймера | |
| TW200843741A (en) | Pharmaceutical composition | |
| US20220184006A1 (en) | Combination therapy | |
| JPWO2020252129A5 (zh) | ||
| JPWO2015129750A1 (ja) | 慢性腎臓病の進行抑制又は改善剤 | |
| JPWO2004002473A1 (ja) | 血糖コントロール用医薬組成物 | |
| JPH1017478A (ja) | 潰瘍性大腸炎の予防又は治療剤 | |
| CN115397431A (zh) | 用于治疗涉及全身过度炎症反应的病症的eclitasertib | |
| US20060121034A1 (en) | Treatment for alzheimer's disease and related conditions | |
| BRPI0906158B1 (pt) | composição farmacêutica de liberação modificada compreendendo doxofilina e processo para a preparação de composição | |
| CA2753754C (en) | Methods for treating schizophrenia | |
| JP5162161B2 (ja) | 炎症性疾患の予防または治療剤 | |
| CN112512526B (zh) | 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途 | |
| WO2024041633A1 (zh) | 一种稠环嘧啶类化合物的用途 | |
| JPH05504130A (ja) | 腫瘍壊死因子拮抗剤 | |
| EP1891971A1 (en) | Medicinal composition for ameliorating or treating glucose intolerance, borderline diabetes, insulin resistance and hyperinsulinemia containing hypoglycemic agent |